Nosocomial candidiasis: Emerging species, reservoirs, and modes of transmission

Clinical Infectious Diseases

Volumn 22, Issue SUPPL. 2, 1996, Pages

  Pfaller, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

CANDIDA ALBICANS; CANDIDIASIS; CONFERENCE PAPER; DISEASE TRANSMISSION; FUNGEMIA; HISTORY OF MEDICINE; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INFECTION RATE; PRIORITY JOURNAL; RESERVOIR; SPECIES DIFFERENTIATION;

EID: 0030017115     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.supplement_2.s89     Document Type: Conference Paper

References (74)

1. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989;11:379-90.
2. Pfaller MA. Epidemiology and control of fungal infections. Clin Infect Dis 1994;19(suppl 1):S8-13.
3. Pfaller MA. Epidemiology of candidiasis. J Hosp Infect 1995;30(suppl): 329-38.
4. Harvey RL, Myers JP. Nosocomial fungemia in a large community teaching hospital. Arch Intern Med 1987;147:2117-20.
5. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-30.
6. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
7. Voss A, Hollis RJ, Pfaller MA, Wenzel RP, Doebbeling BN. Investigation of the sequence of colonization and candidemia in nonneutropenic patients. J Clin Microbiol 1994;32:975-80.
8. Bross J, Talbot GH, Maislin G, Hurwitz S, Strom BL. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989;87:614-20.
9. Karabinis A, Hill C, Leclercq B, Tancrède C, Baume D, Andremont A. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988;26:429-32.
10. Tollemar J, Ringdén O, Boström L, Nilsson B, Sundberg B. Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1989;4:635-41.
11. Weese-Mayer DE, Fondriest DW, Brouillette RT, Shulman ST. Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatr Infect Dis J 1987;6:190-6.
12. Wey SB, Mori M, Pfaller NIA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989;149:2349-53.
13. Wiley JM, Smith N, Leventhal BG, et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol 1990;8:280-6.
14. Beck-Sagúe CM, Jarvis WR, National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993;167: 1247-51.
15. Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992;29(suppl A):19-24.
16. Jarvis WR, Edwards JR, Culver DH, et al. Nosocomial infection rates in adult and pediatric intensive care units in the United States. Am J Med 1991;91(suppl 3B):185S-91S.
17. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med 1991;91(suppl 3B):86S-9S.
18. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6:428-42.
19. Glatt AE, Chirgwin K, Landesmann SH. Treatment of infections associated with human immunodeficiency virus. N Engl J Med 1988;318: 1439-48.
20. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 1994;38:1422-4.
21. Rex JH, Pfaller MA, Barry AL, et al. Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 1995;39:40-4.
22. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995;20:115-25.
23. Aisner J, Schimpff SC, Sutherland JC, Young VM, Wiernik PH. Torulopsis glabrata infections in patients with cancer: increasing incidence and relationship to colonization. Am J Med 1976;61:23-8.
24. Akova M, Akalin HE, Uzun Ö, Gür D. Emergence of Candida krusei infections after therapy with oropharyngeal candidiasis with fluconazole [letter]. Eur J Clin Microbiol Infect Dis 1991;10:598-9.
25. Akova M, Akalin HE, Uzun Ö, et al. Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome. Clin Infect Dis 1994;18: 298-304.
26. Blinkhorn RJ, Adelstein D, Spagnuolo PJ. Emergence of a new opportunistic pathogen, Candida lusitaniae. J Clin Microbiol 1989;27:236-40.
27. Cassone A, De Bernardis F, Pontieri E, et al. Biotype diversity of Candida parapsilosis and its relationship to the clinical source and experimental pathogenicity. J Infect Dis 1995;171:967-75.
28. Christenson JC, Guruswamy A, Mukwaya G, Rettig PJ. Candida lusitaniae: an emerging human pathogen. Pediatr Infect Dis J 1987;6:755-7.
29. Goldman M, Pottage JC, Weaver DC. Candida krusei fungemia: report of 4 cases and review of the literature. Medicine (Baltimore) 1993;72:143-50.
30. Guinet R, Chanas J, Goullier A, Bonnefoy G, Ambroise-Thomas P. Fatal septicemia due to amphotericin B-resistant Candida lusitaniae. J Clin Microbiol 1983;18:443-4.
31. Hadfield TL, Smith MB, Winn RE, Rinaldi MG, Guerra C. Mycoses caused by Candida lusitaniae. Rev Infect Dis 1987;9:1006-12.
32. Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985;7:646-55.
33. King D, Frogatt JW, Smith D, et al. Molecular epidemiology of an amphotericin B, 5-FC resistant strain of Candida lusitaniae [abstract no F-1]. In: Proceedings of the 93rd Annual Meeting of the American Society for Microbiology (Atlanta). Washington, DC: American Society for Microbiology, 1993:527.
34. Martino P, Girmenia C, Micozzi A, et al. Fungemia in patients with leukemia. Am J Med Sci 1993;306:225-32.
35. Merz WG, Khazan U, Jabra-Rizk MA, Wu L-C, Osterhout GJ, Lehmann PF. Strain delineation and epidemiology of Candida (Clavispora) lusitaniae. J Clin Microbiol 1992;30:449-54.
36. Pfaller M, Cabezudo I, Koontz F, Bale M, Gingrich R. Predictive value of surveillance cultures for systemic infection due to Candida species. Eur J Clin Microbiol 1987;6:628-33.
37. Pfaller MA, Messer SA, Hollis RJ. Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Diagn Microbiol Infect Dis 1994;20:127-33.
38. Pfaller MA, Messer SA, Hollis RJ. Variations in DNA subtype, antifungal susceptibility, and slime production among clinical isolates of Candida parapsilosis. Diagn Microbiol Infect Dis 1995;21:9-14.
39. Plouffe JF, Brown DG, Silva J Jr, Eck T, Stricof RL, Fekety FR Jr. Nosocomial outbreak of Candida parapsilosis fungemia related to intravenous infusions. Arch Intern Med 1977;137:1686-9.
40. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos MJ. Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med 1993;94:577-82.
41. Warnock DW, Burke J, Cope NJ, Johnson EM, von Fraunhofer NA, Williams EW. Fluconazole resistance in Candida glabrata [letter]. Lancet 1988;2:1310.
42. Weems JJ Jr. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992;14:756-66.
43. Wingard JR, Merz WG, Saral R. Candida tropicalis: a major pathogen in immunocompromised patients. Ann Intern Med 1979;91:539-43.
44. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-7.
45. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37:1847-9.
46. Sandford GR, Merz WG, Wingard JR, Charache P, Saral R. The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis 1980;142:503-9.
47. Wingard JR, Dick JD, Merz WG, Sandford GR, Saral R, Burns WH. Pathogenicity of Candida tropicalis and Candida albicans after gastrointestinal inoculation in mice. Infect Immun 1980;29:808-13.
48. Wingard JR, Dick JD, Merz WG, Sandford GR, Saral R, Burns WH. Differences in virulence of clinical isolates of Candida tropicalis and Candida albicans in mice. Infect Immun 1982;37:833-6.
49. Walsh TJ, Merz WG. Pathologic features in the human alimentary tract associated with invasiveness of Candida tropicalis. Am J Clin Pathol 1986;85:498-502.
50. Isenberg HD, Tucci V, Cintron F, Singer C, Weinstein GS, Tyras DH. Single-source outbreak of Candida tropicalis complicating coronary bypass surgery. J Clin Microbiol 1989;27:2426-8.
51. Doebbeling BN, Hollis RJ, Isenberg HD, Wenzel RP, Pfaller MA. Restriction fragment analysis of a Candida tropicalis outbreak of sternal wound infections. J Clin Microbiol 1991;29:1268-70.
52. Vanden Bossche H, Marichal P, Odds FC, Le Jeune L, Coene M-C. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1992;36:2602-10.
53. Wickerham LJ. Apparent increase in frequency of infections involving Torulopsis glabrata: procedure for its identification. JAMA 1957;165:47-8.
54. Kaufmann CS, Merz WG. Electrophoretic karyotypes of Torulopsis glabrata. J Clin Microbiol 1989;27:2165-8.
55. Critchley IA, Douglas LJ. Differential adhesion of pathogenic Candida species to epithelial and inert surfaces. FEMS Microbiol Lett 1985;28:199-203.
56. Strausbaugh LJ, Sewell DL, Ward TT, Pfaller MA, Heitzman T, Tjoelker R. High frequency of yeast carriage on hands of hospital personnel. J Clin Microbiol 1994;32:2299-300.
57. Branchini ML, Pfaller MA, Rhine-Chalberg J, Frempong T, Isenberg HD. Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis. J Clin Microbiol 1994;32:452-6.
58. Iwen PC, Kelly DM, Reed EC, Hinrichs SH. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin Infect Dis 1995;20:342-7.
59. Merz WG, Karp JE, Schron D, Saral R. Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol 1986;24:581-4.
60. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos MJ. Epidemiology of nosocomial acquisition of Candida lusitaniae. J Clin Microbiol 1992;30:3005-8.
61. Richet HM, Andremont A, Tancrede C, Pico JL, Jarvis WR. Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 1991;13:211-5.
62. Reagan DR, Pfaller MA, Hollis RJ, Wenzel RP. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol 1990;28:2733-8.
63. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
64. Meunier-Carpentier F. Chemoprophylaxis of fungal infections. Am J Med 1984;76:652-6.
65. Reents S, Goodwin SD, Singh V. Antifungal prophylaxis in immunocompromised hosts. Ann Pharmacother 1993;27:53-60.
66. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.
67. Burnie JP. Candida and hands. J Hosp Infect 1986;8:1-4.
68. Burnie JP, Matthews R, Lee W, et al. Four outbreaks of nosocomial systemic candidiasis. Epidemiol Infect 1987;99:201-11.
69. Finkelstein R, Reinhertz G, Hashman N, Merzbach D. Outbreak of Candida tropicalis fungemia in a neonatal intensive care unit. Infect Control Hosp Epidemiol 1993;14:587-90.
70. Moro ML, Maffei C, Manso E, Morace G, Polonelli L, Biavasco F. Nosocomial outbreak of systemic candidosis associated with parenteral nutrition. Infect Control Hosp Epidemiol 1990;11:27-35.
71. Sherertz RJ, Gledhill KS, Hampton KD, et al. Outbreak of Candida bloodstream infections associated with retrograde medication administration in a neonatal intensive care unit. J Pediatr 1992;120:455-61.
72. Reagan DR, Pfaller MA, Hollis RJ, Wenzel RP. Evidence of nosocomial spread of Candida albicans causing bloodstream infection in a neonatal intensive care unit. Diagn Microbiol Infect Dis 1995;21:191-4.
73. Rangel-Frausto MS, Houston AK, Bale MJ, Fu C, Wenzel RP. An experimental model for study of Candida survival and transmission in human volunteers. Eur J Clin Microbiol Infect Dis 1994;13:590-5.
74. Pfaller MA. Epidemiology of fungal infections: the promise of molecular typing. Clin Infect Dis 1995;20:1535-9.